NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Esperion Therapeutics Inc (NASDAQ: ESPR)
ESPR Technical Analysis
4
As on 24th Dec 2024 ESPR STOCK Price closed @ 2.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.86 & Strong Buy for SHORT-TERM with Stoploss of 1.46 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ESPRSTOCK Price
Open | 2.24 | Change | Price | % |
High | 2.30 | 1 Day | 0.06 | 2.68 |
Low | 2.18 | 1 Week | 0.05 | 2.22 |
Close | 2.30 | 1 Month | -0.22 | -8.73 |
Volume | 1955743 | 1 Year | 0.79 | 52.32 |
52 Week High 3.83 | 52 Week Low 0.73 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
LMDX | 0.02 | 0.00% |
LCID | 3.20 | 3.23% |
AVGR | 1.45 | 126.56% |
NVDA | 140.22 | 0.39% |
AKTS | 0.04 | 0.00% |
TNXP | 0.39 | -2.50% |
PONO | 1.72 | 2.38% |
TELL | 1.00 | 0.00% |
TSLA | 462.28 | 7.36% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
ESPR Daily Charts |
ESPR Intraday Charts |
Whats New @ Bazaartrend |
ESPR Free Analysis |
|
ESPR Important Levels Intraday
RESISTANCE | 2.53 |
RESISTANCE | 2.46 |
RESISTANCE | 2.41 |
RESISTANCE | 2.37 |
SUPPORT | 2.23 |
SUPPORT | 2.19 |
SUPPORT | 2.14 |
SUPPORT | 2.07 |
ESPR Forecast December 2024
4th UP Forecast | 4.17 |
3rd UP Forecast | 3.57 |
2nd UP Forecast | 3.2 |
1st UP Forecast | 2.83 |
1st DOWN Forecast | 1.77 |
2nd DOWN Forecast | 1.4 |
3rd DOWN Forecast | 1.03 |
4th DOWN Forecast | 0.43 |
ESPR Weekly Forecast
4th UP Forecast | 2.80 |
3rd UP Forecast | 2.64 |
2nd UP Forecast | 2.54 |
1st UP Forecast | 2.44 |
1st DOWN Forecast | 2.16 |
2nd DOWN Forecast | 2.06 |
3rd DOWN Forecast | 1.96 |
4th DOWN Forecast | 1.80 |
ESPR Forecast2024
4th UP Forecast | 8.54 |
3rd UP Forecast | 6.54 |
2nd UP Forecast | 5.3 |
1st UP Forecast | 4.07 |
1st DOWN Forecast | 0.53 |
2nd DOWN Forecast | -0.7 |
3rd DOWN Forecast | -1.94 |
4th DOWN Forecast | -3.94 |
Esperion Therapeutics Inc ( NASDAQ USA Symbol : ESPR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ESPR Other Details
Segment | EQ | |
Market Capital | 237180016.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
ESPR Address
ESPR Latest News
ESPR Business Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service